Next Article in Journal
Multiple Evolutionary Selections Involved in Synonymous Codon Usages in the Streptococcus agalactiae Genome
Next Article in Special Issue
Microarray Study of Pathway Analysis Expression Profile Associated with MicroRNA-29a with Regard to Murine Cholestatic Liver Injuries
Previous Article in Journal
The Role of Sialyl-Tn in Cancer
Previous Article in Special Issue
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(3), 280;

MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma

Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
Liver Research Project Center, Hiroshima University, Hiroshima 734-8551, Japan
Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima 734-8551, Japan
Author to whom correspondence should be addressed.
Academic Editors: Nalini Santanam and William Chi-shing Cho
Received: 19 January 2016 / Revised: 19 January 2016 / Accepted: 19 February 2016 / Published: 24 February 2016
(This article belongs to the Special Issue MicroRNA in Various Disease States as Biomarkers)
Full-Text   |   PDF [547 KB, uploaded 24 February 2016]   |  


Serum levels of liver enzymes, such as alanine transaminase, aspartate transaminase, and α-fetoprotein, provide insight into liver function and are used during treatment of liver disease, but such information is limited. In the case of hepatocellular carcinoma (HCC), which is often not detected until an advanced stage, more sensitive biomarkers may help to achieve earlier detection. Serum also contains microRNAs, a class of small non-coding RNAs that play an important role in regulating gene expression. miR-122 is specific to the liver and correlates strongly with liver enzyme levels and necroinflammatory activity, and other microRNAs are correlated with the degree of fibrosis. miR-122 has also been found to be required for hepatitis C virus (HCV) infection, whereas other microRNAs have been shown to play antiviral roles. miR-125a-5p and miR-1231 have been shown to directly target hepatitis B virus (HBV) transcripts, and others are up- or down-regulated in infected individuals. MicroRNA profiles also differ in the case of HBV and HCV infection as well as between HBeAg-positive and negative patients, and in patients with occult versus active HBV infection. In such patients, monitoring of changes in microRNA profiles might provide earlier warning of neoplastic changes preceding HCC. View Full-Text
Keywords: microRNA; non-coding RNA; viral hepatitis; inflammation; occult HBV; hepatocellular carcinoma; fibrosis; HBe antigen; α-fetoprotein; biomarker microRNA; non-coding RNA; viral hepatitis; inflammation; occult HBV; hepatocellular carcinoma; fibrosis; HBe antigen; α-fetoprotein; biomarker

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hayes, C.N.; Chayama, K. MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma. Int. J. Mol. Sci. 2016, 17, 280.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top